Pfizer/Ligand Fablyn delayed
Executive Summary
FDA issues "complete response" letter for Pfizer/Ligand's osteoporosis drug Fablyn (lasofoxifene) Jan. 16. FDA has expressed concern with an apparent increase in mortality among Fablyn patients. FDA's Reproductive Health Drugs Advisory Committee found that trend to be inconclusive during a Sept. 8 meeting, and voted 9-3 (with one abstention) that there was a population of post-menopausal women with osteoporosis for which the use of Fablyn outweighed the risks (1"The Pink Sheet," Sept. 15, 2008, p. 3). Pfizer proposed a 50,000-patient post-marketing safety cohort study to help resolve the issue
You may also be interested in...
Fablyn Panel Finds Mortality Trend Inconclusive, But Pfizer Ready With A Plan
FDA's Advisory Committee for Reproductive Health Drugs did not reach a clear conclusion on whether Pfizer's osteoporosis drug Fablyn has a mortality issue - but Pfizer already has a proposal for a post-market study to provide a definitive answer
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.